ES2536558T3 - Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno - Google Patents

Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno Download PDF

Info

Publication number
ES2536558T3
ES2536558T3 ES09788621.2T ES09788621T ES2536558T3 ES 2536558 T3 ES2536558 T3 ES 2536558T3 ES 09788621 T ES09788621 T ES 09788621T ES 2536558 T3 ES2536558 T3 ES 2536558T3
Authority
ES
Spain
Prior art keywords
tetracycle
heptacosa
triaza
dioxa
decene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09788621.2T
Other languages
English (en)
Spanish (es)
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
CTI Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTI Biopharma Corp filed Critical CTI Biopharma Corp
Application granted granted Critical
Publication of ES2536558T3 publication Critical patent/ES2536558T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22Tricarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D201/00Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02Preparation of lactams
    • C07D201/10Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
ES09788621.2T 2008-12-11 2009-12-09 Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno Active ES2536558T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US121668P 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (1)

Publication Number Publication Date
ES2536558T3 true ES2536558T3 (es) 2015-05-26

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09788621.2T Active ES2536558T3 (es) 2008-12-11 2009-12-09 Sal citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno

Country Status (23)

Country Link
US (2) US8980873B2 (https=)
EP (1) EP2376499B1 (https=)
JP (1) JP5669748B2 (https=)
KR (1) KR101729918B1 (https=)
CN (1) CN102282148B (https=)
AR (2) AR074724A1 (https=)
AU (1) AU2009325147B2 (https=)
BR (1) BRPI0922736B1 (https=)
CA (1) CA2746058C (https=)
DK (1) DK2376499T3 (https=)
ES (1) ES2536558T3 (https=)
HR (1) HRP20150428T1 (https=)
IL (3) IL213418A0 (https=)
MX (1) MX2011006206A (https=)
MY (1) MY160005A (https=)
NZ (1) NZ593223A (https=)
PL (1) PL2376499T3 (https=)
PT (1) PT2376499E (https=)
RU (1) RU2527970C2 (https=)
SG (1) SG171907A1 (https=)
TW (1) TWI449705B (https=)
WO (1) WO2010068181A1 (https=)
ZA (1) ZA201104032B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2376499T3 (pl) 2008-12-11 2015-07-31 Cti Biopharma Corp Sól cytrynianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26-triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu
DK2376500T3 (en) * 2008-12-11 2015-05-04 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt
WO2013163917A1 (zh) 2012-04-13 2013-11-07 连云港金康和信药业有限公司 化合物jk12a及其制备
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
EE200300557A (et) * 2001-05-14 2004-04-15 Pfizer Products Inc. 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1461040B1 (en) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
PL2376499T3 (pl) 2008-12-11 2015-07-31 Cti Biopharma Corp Sól cytrynianowa 11-(2-pirrolidyn-1-yloetoksy)-14,19-dioksa-5,7,26-triazatetracyklo[19.3.1.1(2,6).1(8,12)]heptakosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaenu

Also Published As

Publication number Publication date
AR114133A2 (es) 2020-07-22
HK1161877A1 (en) 2012-08-10
CA2746058A1 (en) 2010-06-17
SG171907A1 (en) 2011-07-28
RU2011126173A (ru) 2013-01-20
BRPI0922736B1 (pt) 2022-02-22
RU2527970C2 (ru) 2014-09-10
AR074724A1 (es) 2011-02-09
KR20110106344A (ko) 2011-09-28
US20110294831A1 (en) 2011-12-01
AU2009325147B2 (en) 2014-08-14
BRPI0922736A2 (pt) 2017-10-31
EP2376499B1 (en) 2015-02-25
US20150322084A1 (en) 2015-11-12
CN102282148A (zh) 2011-12-14
AU2009325147A1 (en) 2011-06-23
TWI449705B (zh) 2014-08-21
NZ593223A (en) 2013-08-30
BRPI0922736A8 (pt) 2021-11-09
MY160005A (en) 2017-02-15
PL2376499T3 (pl) 2015-07-31
IL250310A0 (en) 2017-03-30
WO2010068181A8 (en) 2011-08-18
CN102282148B (zh) 2014-12-24
HRP20150428T1 (xx) 2015-06-19
IL289379A (en) 2022-02-01
KR101729918B1 (ko) 2017-04-25
US9624242B2 (en) 2017-04-18
JP5669748B2 (ja) 2015-02-12
MX2011006206A (es) 2011-07-20
EP2376499A1 (en) 2011-10-19
TW201028426A (en) 2010-08-01
PT2376499E (pt) 2015-06-03
ZA201104032B (en) 2012-08-29
JP2012511571A (ja) 2012-05-24
DK2376499T3 (en) 2015-05-04
US8980873B2 (en) 2015-03-17
IL213418A0 (en) 2011-07-31
WO2010068181A1 (en) 2010-06-17
CA2746058C (en) 2016-05-17

Similar Documents

Publication Publication Date Title
NL301021I1 (nl) talazoparib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout.
CR20110432A (es) Pirimidinas fusionadas
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA200801959A1 (ru) Высокоразветвленный полипропилен
BRPI0822775A2 (pt) Método de obtenção de uma proteína heteróloga, purificada, biologicamente ativa.
CY1119121T1 (el) Αμορφο αλας ενος μακροκυκλικου αναστολεα του hcv
EA201000883A1 (ru) Производные индолинона и способ их получения
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
BRPI1010254A2 (pt) "derivados de pirrolidina diona espiroheterocíclica utilizada como pesticida."
IL289379A (en) Citrate salt of 11-(2-pyrrolidin-1-yl-ethoxy)-19,14-dioxa-26,7,5-triaza-tetracyclo[1.1.3.19(6,2)1(12,8)]hepatacosa- 1(25),2(26),12,10,8,5,3(27)j23,21,16–Decan
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
AR114987A2 (es) Sal de citrato del 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1.(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno
DOP2006000233A (es) Inhibidores de cinasa
HRP20181437T1 (hr) Postupak proizvodnje (3s,3s') 4,4' disulfanedilbis (3-aminobutan-1-sulfonske kiseline)
EA200900816A1 (ru) Антибактериальные соединения и способы их получения
PT2376500E (pt) Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa- 5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno
EA201300719A3 (ru) Способ ферментативного синтеза (7s)-1-(3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-ил) n-метилметанамина, и применение в синтезе ивабрадина и его солей
EA200970692A1 (ru) Способы улучшения стабильности стероидных производных
ITMO20050182A1 (it) Ago per biopsia dei tessuti molli.
PL2300024T3 (pl) Sposób zmniejszania burczenia brzucha przez podawanie bakterii Bifidobacterium
IL194337A0 (en) Method for preparing lysobactin derivatives
DE602006014001D1 (de) Herstellung von 2-aminothiazol-5-carbonsäurederivaten
EA201170509A1 (ru) Селективный модулятор рецепторов эстрогена
EA200901229A1 (ru) Новый способ получения левоцетиризина и его промежуточных соединений